Canada gets cystinosis eye drops

Cystinosis is a rare genetic disease, but the eye problem it causes is brutally concrete. Cystine crystals build up in the cornea — the clear front window of the eye — and patients can end up with pain, glare, photophobia, and long-term vision damage if that buildup is not controlled. The news here is that Canada now has a branded, approved eye-drop option for that specific problem: Cystadrops, a cysteamine ophthalmic solution sold by Recordati. Health Canada lists it as an authorized prescription drug for sale in Canada. (health-products.canada.ca) ### What is the drug, exactly? Cystadrops is a topical cysteamine treatment made for corneal cystine crystal deposits in people with cystinosis. The active drug depletes cystine, which is the substance forming those crystals in the cornea. That sounds narrow, but it is narrow in the useful way — this is not a general dry-eye drop or a steroid. It is aimed at the core chemistry of the eye disease. (drugs.com) ### Why do patients need eye drops at all? Systemic cysteamine helps the body overall, especially the kidneys, but it does not solve the cornea well enough on its own. The cornea has no blood vessels, so drugs taken by mouth do not reach it the same way they reach other tissues. That is why ocular cystinosis has always needed local treatment — actual drops on the eye, over and over, for years. (ema.europa.eu)ps)) ### Why is this a meaningful change? Because “approved commercial drop” is different from “something patients patch together.” Before products like Cystadrops, many patients relied on compounded cysteamine drops that were harder to access, less convenient, and often needed very frequent dosing. Cystadrops was designed as a viscous formulation so it stays on the eye longer, which is the whol(ema.europa.eu)ents. (recordati.com) ### How often is it used? The practical detail that stands out is dosing burden. EMA product information describes a median regimen of 3 drops per eye per day in the supporting data, with a ceiling of 4 drops a day in each eye. That is still a chronic therapy, obviously, but it is a lot more manageable than the older reality many cystinosis patients knew. (ema.europa.eu).pdf)) ### Does it actually reduce the crystals? Basically, yes — that is the reason the drug exists. In the clinical data reviewed in Europe, average corneal crystal deposits fell by about 30% from baseline and that reduction was maintained over time in the small study population. This is a rare-disease drug, so the datasets are not huge, but the direction of benefit is clear enough that regulators in multiple regions authorized it. (ema.europa.eu) ### What does “available in Canada” mean here? It means more than a social-media mention. Health Canada’s Notice of Compliance shows Cystadrops received approval on February 11, 2019, under a priority review, and the Drug Product Database lists it with DIN 02485605. Recordati also maintains a Canada product page, which lines up with the product being commercially present rather than just theoretically approved. (health-products.canada.ca) ### Who benefits most from this? Patients with nephropathic cystinosis and persistent corneal crystal disease are the obvious group, but the real winner is day-to-day adherence. Rare diseases often turn on boring logistics — refrigeration, pharmacy compounding, refill timing, how many times a parent or patient has to dose in a school day. A thicker, approved drop does not cure cystinosis, but it makes long-haul eye care more doable. (recordati.com) ### Bottom line This is a small-market drug for a very small patient population, but it fixes a very real treatment gap. Canada now has an approved cystinosis eye drop on the market — and for patients dealing with corneal crystals every day, convenience is not cosmetic. It is part of whether treatment actually happens. (health-products.canada.ca)